Startups
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
Overview
Location
United States, California, La Jolla
Employees
11-50
Total raised
$36M
Founded date
2007
Investors 6
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Bioscience Managers | biosciencemanagers.com | |
| Valence Life Sciences | valencefund.com | |
| Aug 30, 2023 | OrbiMed | orbimed.com |
| Quark Venture | quarkventure.com | |
| Golden Falcon Capital | falconcapital.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| May 25, 2020 | Series C round | $15M |
Persons 1
| Date | First Name | Last Name | Title | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 9, 2021 | CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways | |
| Jun 2, 2021 | CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study | |
| Mar 11, 2021 | CalciMedica Announces $21 Million Series D Financing | Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Za... |
| Mar 11, 2021 | CalciMedica has raised a $21M Series D to advance their anti-inflamatory therapy currently being evaluated for severe and critical COVID-19 Pneumonia and acute pancreatitis with SIRS | |
| May 25, 2020 | CalciMedica Raises $15M in Series C Financing | CalciMedica Inc., a La Jolla, Calif.-based clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, raised $15m in Series C financing. The ... |
| May 22, 2020 | CalciMedica Raises $15M in Series C Financing | |
| Dec 15, 2009 | CalciMedica Closes Second Tranche of $12M Series C Financing | CalciMedica, a La Jolla, California-based biotechnology company dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases, announced the closing of the second tranche ... |
| Feb 12, 2008 | Life sciences briefing: Tuesday, Feb. 12, 2008 | TODAY’S HEADLINES: Metabolic-disease biotech NGM Biopharma raises $25M (peHUB) Heart, HIV drug maker Numerate acquires assets of Pharmix (release) Next-gen sequencer VisiGen promises $1,000 genome by late 2009 (Genome Technology) CalciMedic... |
| Jul 31, 2007 | CalciMedica raises $1.5M for inflammatory disease | CalciMedica, a San Diego biotech focused on autoimmune and inflammatory disease, raised $1.53 million in a first funding round, PE Hub reports, citing a regulatory filing. S.R. One provided the funding. VentureBeat VentureBeat's mission is ... |
Show more
Reviews 0
FAQ about CalciMedica
When was CalciMedica founded?
CalciMedica was founded in 2007.
How much funding has CalciMedica raised?
CalciMedica has raised $36M in total across 2 funding rounds.
What funding rounds has CalciMedica raised?
Parsers VC lists 2 funding rounds of CalciMedica, among them a Series C round of $15M on May 25, 2020.
Who has invested in CalciMedica?
Parsers VC lists 6 investors of CalciMedica, among them OrbiMed, Bioscience Managers and Valence Life Sciences.
What has the press written about CalciMedica?
Parsers VC has collected 11 articles mentioning CalciMedica, among them “CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug T...” (Sep 9, 2021) and “CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study” (Jun 2, 2021).
Is CalciMedica still active?
Yes, CalciMedica is active; its latest activity on Parsers VC dates from Jul 10, 2026.